Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DAA-PASS: A Post-Authorisation Safety Study of Early Recurrence of Hepatocellular Carcinoma in HCV-Infected Patients After Direct-Acting Antiviral Therapy

NCT03707080 is registered in ClinicalTrials.gov with Target PharmaSolutions, Inc. as lead sponsor.

NCT NCT03707080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03707080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DAA-PASS: A Post-Authorisation Safety Study of Early Recurrence of Hepatocellular Carcinoma in HCV-Infected Patients After Direct-Acting Antiviral Therapy
Lead sponsor
Target PharmaSolutions, Inc.
Phase
Observational
Overall status
Completed
Start date
March 9, 2018
Completion date
June 30, 2021
Enrollment
42 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, hepatocellular carcinoma